Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;72(5):728-35.
doi: 10.1136/annrheumdis-2012-201381. Epub 2012 Jun 26.

Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression

Zana Brkic  1 , Naomi I Maria, Cornelia G van Helden-Meeuwsen, Joop P van de Merwe, Paul L van Daele, Virgil A Dalm, Manon E Wildenberg, Wouter Beumer, Hemmo A Drexhage, Marjan A Versnel
Affiliations

Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression

Zana Brkic et al. Ann Rheum Dis. 2013 May.

Abstract

Objective: To determine the prevalence of upregulation of interferon (IFN) type I inducible genes, the so called 'IFN type I signature', in CD14 monocytes in 69 patients with primary Sjögren's syndrome (pSS) and 44 healthy controls (HC) and correlate it with disease manifestations and expression of B cell activating factor (BAFF).

Methods: Expression of IFI44L, IFI44, IFIT3, LY6E and MX1 was measured using real time quantitative PCR in monocytes. Expression values were used to calculate IFN type I scores for each subject. pSS patients positive for the IFN type I signature (IFN score≥10) and patients negative for the signature (IFN score<10) were then compared for clinical disease manifestations and BAFF expression. A bioassay using a monocytic cell line was performed to study whether BAFF mRNA expression was inducible by IFN type I activity in serum of patients with pSS.

Results: An IFN type I signature was present in 55% of patients with pSS compared with 4.5% of HC. Patients with the IFN type I signature showed: (a) higher EULAR Sjögren's Syndrome Disease Activity Index scores; higher anti-Ro52, anti-Ro60 and anti-La autoantibodies; higher rheumatoid factor; higher serum IgG; lower C3, lower absolute lymphocyte and neutrophil counts; (b)higher BAFF gene expression in monocytes. In addition, serum of signature-positive patients induced BAFF gene expression in monocytes.

Conclusions: The monocyte IFN type I signature identifies a subgroup of patients with pSS with a higher clinical disease activity together with higher BAFF mRNA expression. Such patients might benefit from treatment blocking IFN type I production or activity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Gene expression of 11 interferon (IFN) type I inducible genes in patients with primary Sjögren's syndrome (pSS) (n=69) and healthy controls (HC) (n=44). To compare means the Mann–Whitney U test was applied. (B) Heat map showing gene expression of five interferon (IFN) type I inducible genes in monocytes of patients with pSS (n=69) and HC (n=44). On the left the patients with pSS are depicted and subdivided into IFN type I signature-positive patients and IFN type I signature-negative patients. On the right the HC are depicted. Red colour indicates high gene expression. (C) Distribution of IFN scores in IFN type I signature-positive and -negative patients and HC. IFN type I-positive cases are depicted in red. Blue lines depict medians. (D) Heat map showing gene expression of IFN type I inducible genes in monocytes of patients with pSS (n=24) at two different time points (average period between two measurements 3.6±2.5 years). (E) No significant differences detected between two time points using the dependent t test.
Figure 2
Figure 2
(A) EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scores in interferon (IFN) type I signature-positive and -negative patients with primary Sjögren's syndrome (pSS) (n=38). (B) IFN scores in patients with pSS positive or negative for anti-SSA (both Ro52 and Ro60) and anti-SSB (n=69). (C) Rheumatoid factor levels in IFN type I signature-positive and -negative patients with pSS (n=50). (D) IgG levels in IFN type I signature-positive and -negative patients with pSS (n=68). (E) C3 levels in IFN type I signature-positive and -negative patients with pSS (n=46). (F) Absolute lymphocyte levels in IFN type I signature-positive and -negative patients with pSS (n=42). (G) Absolute neutrophil levels in IFN type I signature-positive and -negative patients with pSS (n=41). Independent t test was used to compare means in E–G, where horizontal bars represent the means. Mann–Whitney U test was used to compare means in A–D, where horizontal bars represent the medians. In B medians and IQR are depicted; ** represents p value<0.01 and **** represents p value <0.0001.
Figure 3
Figure 3
(A) B cell activating factor (BAFF) mRNA expression in monocytes in patients with primary Sjögren's syndrome (pSS) (n=69) and healthy controls (HC) (n=44). BAFF mRNA expression was determined by real time quantitative-PCR. (B) Correlation between interferon (IFN) type I score and BAFF mRNA expression in monocytes in patients with pSS (n=69). (C) Induction of BAFF mRNA expression in THP-1 cells by incubation with 50% serum of IFN type I signature-positive patients with pSS (n=9) and IFN type I signature-negative patients with pSS (n=7) in the presence of a blocking IFN type I receptor antibody. Expression is relative compared with the mean expression in HC (n=8). (D) BAFF protein levels in serum of patients with pSS (n=68) and HC (n=42) measured by ELISA. (E) Correlation between serum BAFF protein and IFN scores in patients with pSS (n=68). (F) Correlation between serum BAFF protein and BAFF mRNA expression in monocytes of patients with pSS (n=68). The correlation coefficients (r) and p values are shown. For correlations Spearman's ρ correlation test was used and to compare means the Mann–Whitney U test was used.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009;11:229. - PMC - PubMed
    1. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8 - PMC - PubMed
    1. Wildenberg ME, van Helden-Meeuwsen CG, van de Merwe JP, et al. Systemic increase in type I interferon activity in Sjogren's syndrome: a putative role for plasmacytoid dendritic cells. Eur J Immunol 2008;38:2024–33 - PubMed
    1. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006;103:2770–5 - PMC - PubMed
    1. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534–44 - PubMed

Publication types

-